Recently, the transdermal route has vied with oral treatment as the most
successful innovative research area in API delivery. In the USA (the most
important pharmaceutical market), out of 129 API delivery products
under clinical evaluation, 51 are transdermal or dermal systems; 30% of 77
candidate products in preclinical development represent such API
delivery. The worldwide transdermal patch market approaches $20 billion,
yet is based on only 20 drugs. This rather limited number of drug
substances is attributed to the excellent barrier function of the skin, which
is accomplished almost entirely by the outermost 10–15 μm (in the dry
state) of tissue, the stratum corneum (SC). Before being taken up by blood
vessels in the upper dermis and prior to entering the systemic circulation,
substances permeating the skin must cross the SC and the viable
epidermis.
Write your review for this book (optional)
Review Deleted
Your review has been deleted and won’t appear on the book anymore.
Dr. Dilpreet Singh, Karan Razdan, Pooja Chawla
Dr. Dilpreet Singh is working as an assistant professor in university institute of pharmaceutical sicences, chandigarh university, kharar india
